MedDO and the MRA: a new medtech border

In May 2021, a Swiss manufacturer could still have a compliant product yet lose the straightforward route into the European Union. In the other direction, an EU manufacturer could retain its CE certificate but encounter new Swiss obligations. The product had not changed; the regulatory border had. This reading reconstructs that shift without using compliance as a fear tactic. It explains what the failure to update the mutual recognition agreement actually removed, what Switzerland's Medical Devices Ordinance maintained, and how responsibilities are divided between the Swiss authorised representative, importer, CHRN and vigilance functions. It then follows the swissdamed deadline that opened in July 2026. The strategic task is to identify businesses that must act now, separate a documentation issue from a market-access decision, and define a useful initial service. A certificate, deadline or company list can never establish revenue on its own.

The failure to update the Switzerland–EU MRA removed selected recognition and cooperation arrangements for devices under the new rules. It neither made Swiss law identical to EU law nor invalidated CE certificates in Switzerland. Businesses must now distinguish the target market, operators' place of establishment, required representation and conformity route.

The MRA covers mutual recognition of conformity assessments. Before 26 May 2021, its medical-device chapter facilitated trade between Switzerland and the European Union. When the EU Medical Devices Regulation became fully applicable, that chapter was not updated. The European Commission consequently treated Switzerland as a third country for devices under the new regulation.

There was no legal vacuum. Switzerland had revised its Medical Devices Ordinance, MedDO, to preserve an equivalent level of safety and continued to recognise compliant EU-assessed devices unilaterally. CE marking can therefore still support Swiss market access, but reciprocity and selected cooperation mechanisms under the agreement are no longer assured.

Three concepts must remain separate. Equivalence means technical requirements follow similar logic. Mutual recognition simplifies acceptance of selected assessments between territories. Market access depends on the product, class, evidence and operators placing it on the market. None automatically replaces the others.

How to read the diagram. The MRA situation does not decide a product's fate. It requires a chain of checks: evidence, establishment, representation, import, registration and surveillance.

Diagram source. Federal Office of Public Health, medical-device legislation; European Commission notice to stakeholders of 26 May 2021.

MedDO 2021 does not require a Swissmedic authorisation comparable to a medicinal-product licence. Medical devices follow a conformity assessment suited to their risk class, often involving a private conformity assessment body. Swissmedic performs market surveillance, registers selected operators and receives mandatory reports, but does not issue a general commercial permit.

A manufacturer does not simply file with Swissmedic and receive universal clearance. It must demonstrate compliance with the applicable requirements, maintain the required documentation, organise post-market surveillance and fulfil the obligations attached to its economic operators.

Swissmedic supervises the market, inspects operators within its remit, receives serious-incident and field safety corrective action reports, and runs Swiss registration systems. The manufacturer nevertheless remains responsible for the device. A claim such as “we obtain your Swissmedic approval” would therefore be misleading. A sound offer makes the route intelligible: qualify the product, identify responsible parties, inventory missing information and refer interpretive questions to an authorised specialist.

Each operator in the Swiss chain has a distinct duty: the manufacturer is responsible for the device, the Swiss authorised representative performs the tasks in its mandate, the importer checks and traces what it places on the market, and the distributor controls its supply activity. Actual function and place of establishment matter more than a commercial title.

One company may have different roles by product or transaction. A Swiss distributor becomes an importer when it first places a foreign device on the Swiss market. A local group company is not automatically the representative for every product. The mandate, ownership flow and records must establish the function.

How to read the table. Qualification starts with an observable relationship between a device, company and market, not with a prospect list. Campaigns should exclude accounts whose role cannot be established.

A Swiss authorised representative is required when a manufacturer established outside Switzerland places a device on the Swiss market for which MedDO requires a Swiss-based person to perform defined tasks. The need depends on establishment, product and applicable provisions; an importer or distributor does not become the representative without the corresponding written mandate.

The Swiss authorised representative, often called the CH-REP, is more than an address on a label. It represents a named manufacturer for defined regulatory tasks, potentially including document retention, cooperation with Swissmedic and handling selected requests. The relationship must be understood before it is sold.

The function may support recurring work, but revenue depends on the portfolio, risk, surveillance workload, insurance, liability clauses and partner capacity. A narrower first purchase is often better: map devices and operators, then document the likely mandate scope. The manufacturer can decide whether to appoint a CH-REP, revise an existing contract or complete information. Strong acquisition signals include a stated Swiss launch, named product, representative change, new distribution or unregistered portfolio.

A CHRN does not prove device registration because it identifies a Swiss economic operator in Swissmedic's system. Devices have their own data and registration duties. Confusing the two can make a portfolio appear ready when only the manufacturer, authorised representative or importer has been identified.

The Swiss registration number answers “who is the operator?” Device records answer “which product, which UDI, which manufacturer, which status and which Swiss-market relationship?” An organisation may have completed actor registration while its catalogue remains unfinished.

How to read the visual. A useful commercial audit locates the incomplete layer. It avoids selling a full redesign when only a link, portfolio check or clarification of responsibility is needed.

Since 1 July 2026, swissdamed has made registration of relevant devices, systems and procedure packs mandatory in its UDI Devices module. Manufacturers and authorised representatives generally have until 31 December 2026 to complete the backlog, while selected vigilance events require immediate registration. Importers follow a separate linking timetable.

The national database turns an abstract duty into a data project. Manufacturers and representatives must prepare devices placed on the Swiss market, verify identifiers, assign roles and handle exceptions. Legacy devices that remain on the market also fall within the scope described by Swissmedic.

The 31 December date is not universal grace. A device tied to a serious incident, field safety corrective action or trend report must be registered immediately from 1 July 2026. Selected reports continue through forms, so the portfolio needs segmentation before workload is estimated.

Importers do not register devices instead of manufacturers or representatives. They link their actor record to a device already registered. Swissmedic planned progressive availability of this function in autumn 2026 and a first compliance deadline of 1 April 2027, subject to its announced conditions. Optical devices cited by the authority follow a particular timetable.

How to read the timeline. Manufacturers and representatives may need immediate preparation and registration. Importers may first need to inventory their portfolio and improve source data.

Timeline source. Swissmedic publications on swissdamed registration and importer duties, consulted in August 2026.

Accounts merit contact when they show a verifiable product and event: Swiss entry, a portfolio to register, representative change, importer linking, an incident requiring immediate action or a cross-border launch. Being categorised as medtech reveals no current need, decision-maker, budget or ability to buy.

Qualification combines six items: named product, company role, target market, dated event, responsible person and next decision. Signals may come from launch announcements, regulatory recruitment, distribution partnerships, public documentation or direct discussion. Each must be confirmed; no single signal creates a mandate.

The closest account to a purchase is not necessarily the largest. A foreign manufacturer preparing its first Swiss units may have an urgent, tightly bounded decision. An established importer may carry a broader catalogue but depend on device data that manufacturers have not yet entered. A Swiss authorised representative may need temporary preparation capacity while retaining its regulatory responsibility. For a 2026 market-entry or registration programme, the first conversation therefore tests the product, role, deadline and internal owner before discussing channels or campaign volume.

A useful account brief records the evidence behind each fact, what remains uncertain and who can resolve it. This prevents a public deadline from being mistaken for buyer intent and gives the partner a defensible reason to contact one organisation rather than every company labelled medtech.

How to read the chart. The scale ranks information quality. It is not prospect volume, conversion data or campaign performance.

The initial service can be a paid Swiss-market readiness diagnostic: product inventory, operator qualification, available-data review and an action plan for the competent owners. It can sell quickly when the partner has validated capacity, insurance and pricing, but this article proves neither collection time nor margin.

The deliverable may include a product–operator matrix, missing information, dependencies between manufacturer, representative and importer, and a processing order. It must not certify a device, give unauthorised legal advice or guarantee acceptance of a registration.

Follow-on work may cover data preparation or entry, a Swiss representative function where the organisation and contracts allow, or longer-term portfolio coordination. Recurrence can be claimed only after real contracts, costs and renewals are observed. Revenue within thirty days is plausible only if accounts, proposition, decision-maker, partner capacity and invoicing are already in place. The economic verdict is therefore a conditional green light for a bounded swissdamed test, not a generic “MedDO 2021” campaign.

A credible medtech acquisition strategy promises qualification and connection, never guaranteed compliance. It combines targeted search, partners, content, events and direct outreach around a documented signal. Every channel leads to the same diagnostic, while regulatory owners retain product and obligation decisions.

Web search can capture questions on swissdamed, CHRN or Swiss representation. Email and phone can reach manufacturers announcing Swiss entry or importers with an identifiable portfolio. Professional networks and events identify regulatory, quality, operations and management owners. Partners may reveal complementary needs without sharing confidential information.

How to read the journey. A meeting is not the outcome. Value appears when an event becomes a purchasable diagnostic and then an assignment the partner can deliver.

The 2026 SECO study measures additional costs associated with the non-updated MRA among surveyed businesses. It measures neither demand for a particular provider nor campaign conversion. It shows varied economic burdens, with a greater effect on selected SMEs, and states its own uncertainties.

The institutional summary estimates average one-off costs of 0.3% to 0.7% of export turnover for surveyed Swiss manufacturers and 0.6% to 0.7% of import turnover for distributors or importers. Estimated annual recurring costs are 0.10% to 0.14% for manufacturers and 0.3% to 0.4% for distributors.

These figures give the problem scale, not a sales price. The study notes a small sample, heterogeneous effects and substantial uncertainty. It also reports market adaptation through consolidation and portfolio changes. Segmentation by cross-border exposure, size and role is justified; converting a turnover percentage into available budget is not.

Before launch, the team must evidence a renewable pool of new accounts, a clear initial purchase, accepted pricing, full cost, margin, collection time and partner capacity. Insurance, responsibilities and regulatory escalation must also be checked. Without them, swissdamed remains a commercial hypothesis on hold.

The minimum evidence is not a market estimate but a comparable, anonymisable transaction: initial need, deliverable, order date, invoiced amount, collection, time used and any follow-on. Recalculate the pool after excluding accounts without an identified Swiss product, already served companies, uncertain roles, irrelevant timetables and cases the partner cannot handle.

How to read the table. Testing begins only when every item has an owner and verification method. An unresolved row narrows the scope or keeps publication on hold.

The complimentary eligibility test checks whether your acquisition challenge matches an actionable medtech window: identifiable targets, a current event, initial purchase, delivery capacity and possible margin. It does not validate a device or replace a regulatory specialist.

We compare your current challenge—broad targeting, inaccessible decision-makers, a complex regulatory offer, weak qualification or reliance on a few referrers—with the signals and scope you can serve. A genuine fit leads to a tailored qualification, message, channel and decision framework, while you retain responsibility for your services and clients.